Viridian Therapeutics (VRDN) AI Stock Analysis

• Market Cap: $3.07B
• Dividend Yield: N/A
• Average Volume (3M): 814.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: 23340.07%
• EPS Growth: 18.06%
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 95,442,010
• 10 Day Avg. Volume: 1,087,693
• 30 Day Avg. Volume: 814,586
• PEG Ratio: 0.19
• Price to Book (P/B): 1.94
• Price to Sales (P/S): 4309.19
• P/FCF Ratio: -5.59
• Enterprise Value/Market Cap: 0.26
• Enterprise Value/Revenue: 11.15
• Enterprise Value/Gross Profit: 11.15
• Enterprise Value/Ebitda: -2.64
• 1Y Price Target: $40.87
• Price Target Upside: 29.33% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: $33.00 ▲(4.43% Upside)

Viridian Therapeutics' overall score is driven by strong technical momentum and positive corporate events, which enhance its financial position. However, the score is tempered by ongoing profitability challenges and a negative P/E ratio. Investors should monitor the company's progress in achieving milestones and improving cash flow.

Positive Factors

Revenue Growth

Significant revenue growth indicates strong demand for Viridian's therapies, enhancing its market position and potential for profitability.

Strategic Partnerships

The $300M deal with DRI Healthcare provides substantial funding, supporting R&D and growth, and strengthens Viridian's financial position.

Low Leverage

Low leverage enhances financial stability, allowing Viridian to invest in growth opportunities without overburdening its balance sheet.

Negative Factors

Profitability Challenges

Ongoing profitability challenges could hinder Viridian's ability to sustain operations and fund future growth without external financing.

Negative Cash Flow

Negative cash flow can strain operational capabilities, necessitating improved cash generation to support long-term sustainability.

Ongoing Losses

Continued losses may impact investor confidence and limit Viridian's ability to attract new capital, affecting future growth prospects.

Viridian Therapeutics Business Overview & Revenue Model

Company Description

Viridian Therapeutics (VRDN) is a biopharmaceutical company focused on developing innovative therapies for patients with serious and rare diseases. The company operates in the biotechnology sector and specializes in the discovery and development of monoclonal antibodies that target specific disease mechanisms. Viridian's core products include biologic therapies aimed at treating conditions such as thyroid eye disease and other autoimmune disorders, leveraging its proprietary technology platforms to create novel treatment options.

How the Company Makes Money

Viridian Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company's revenue model includes potential sales from approved drugs, milestone payments from partnerships, and royalties on product sales. Key revenue streams may arise from collaborations with larger pharmaceutical companies that provide funding for research and development in exchange for future profits or product rights. Additionally, Viridian may seek to monetize its product pipeline through licensing agreements or partnerships that allow it to share development costs and risks while gaining access to broader distribution channels.

Viridian Therapeutics Financial Statement Overview

Summary

Viridian Therapeutics is experiencing significant revenue growth, but profitability and cash flow remain challenging. The balance sheet is stable with low leverage, yet ongoing losses could pose risks if not addressed. The company should focus on improving operational efficiency and cash flow management.

Income Statement

Viridian Therapeutics shows significant revenue growth in the TTM period, but profitability remains a major concern with negative net profit margins and EBIT margins. The company is experiencing high operating losses, which is typical for biotechnology firms in the development phase.

Balance Sheet

The company maintains a low debt-to-equity ratio, indicating conservative leverage. However, the negative return on equity reflects ongoing losses, which could be a risk if not managed well. The equity ratio is stable, suggesting a solid asset base relative to liabilities.

Cash Flow

Free cash flow is negative, but there is slight growth in the TTM period. The operating cash flow to net income ratio is unfavorable, indicating cash flow challenges. The company needs to improve cash generation to support its operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	70.79M	302.00K	314.00K	1.77M	2.96M	1.05M
Gross Profit	70.79M	302.00K	314.00K	1.77M	2.96M	-27.25M
EBITDA	-298.99M	-265.66M	-235.37M	-129.13M	-79.29M	-40.28M
Net Income	-301.97M	-269.95M	-237.73M	-129.87M	-79.41M	-110.72M
Balance Sheet
Total Assets	577.14M	742.40M	490.42M	435.09M	203.71M	131.25M
Cash, Cash Equivalents and Short-Term Investments	490.90M	717.58M	477.37M	424.55M	196.97M	127.64M
Total Debt	23.82M	21.09M	21.05M	5.26M	520.00K	455.00K
Total Liabilities	74.17M	70.76M	48.40M	40.03M	15.99M	11.22M
Stockholders Equity	502.97M	671.64M	442.02M	395.06M	187.72M	120.04M
Cash Flow
Free Cash Flow	-326.34M	-232.83M	-185.07M	-94.64M	-54.92M	-29.82M
Operating Cash Flow	-325.97M	-232.32M	-184.17M	-93.84M	-54.58M	-29.78M
Investing Cash Flow	238.94M	-228.65M	-94.25M	-115.13M	-74.29M	-50.48M
Financing Cash Flow	56.36M	457.74M	225.67M	322.24M	125.28M	101.31M

Viridian Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 31.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRDN, the sentiment is Neutral. The current price of 31.6 is below the 20-day moving average (MA) of 31.77, above the 50-day MA of 27.47, and above the 200-day MA of 18.86, indicating a neutral trend. The MACD of 1.36 indicates Positive momentum. The RSI at 57.66 is Neutral, neither overbought nor oversold. The STOCH value of 37.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VRDN.

Viridian Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DNTH	61 Neutral	$1.78B	-11.96	-28.57%	―	-42.64%	-39.78%
VRDN	60 Neutral	$3.07B	-8.94	-47.40%	―	23340.07%	18.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JANX	45 Neutral	$848.08M	-8.38	-12.48%	―	-23.37%	-42.45%
PHVS	42 Neutral	$1.54B	-7.46	-51.81%	―	―	-20.08%
EWTX	40 Underperform	$2.36B	-13.41	-30.02%	―	―	-5.73%
BHVN	40 Underperform	$1.44B	-1.46	-522.08%	―	―	18.76%

Viridian Therapeutics Corporate Events

Viridian Therapeutics Announces Stock Sale Agreement

On October 21, 2025, Viridian Therapeutics announced an underwriting agreement for the sale of 11,425,000 shares of common stock at $22.00 per share, potentially raising approximately $251.35 million. The proceeds, combined with other financial resources, are expected to fund the company’s operations, including anticipated revenue from product sales and milestone payments, although the company acknowledges potential risks and uncertainties in its financial projections.

Viridian Therapeutics Secures $300M Deal with DRI Healthcare

On October 17, 2025, Viridian Therapeutics entered into a Purchase and Sale Agreement with DRI Healthcare Acquisitions, selling rights to certain revenue streams in the U.S. for up to $300 million. This agreement includes payments contingent on achieving specific clinical and regulatory milestones for its products VRDN-003 and veligrotug. Additionally, Viridian amended its Loan and Security Agreement with Hercules Capital, securing a new term loan facility of up to $300 million, structured in tranches contingent on regulatory and revenue milestones, with a maturity date set for October 17, 2030.